Skin Cancer, Sarcomas, and Unknown Primary Site

D.K., 52, three weeks into training for his tenth half-marathon when a mole his wife had asked about for a year finally got checked. The disagreement is whether his brain metastases and remote weekend routine argue for the safer drug or against it once the real intracranial trial data is read.

R.O., 46, six weeks from her son's wedding and finishing centerpieces at her kitchen table rather than resting. The disagreement is whether immunotherapy's real survival advantage is worth its slower onset when there's a date on the calendar she's determined to be well for.

G.F., 63, an electrician who has rewired more houses than he can count, now with a new nodal mass his wife found. The disagreement is whether starting immunotherapy before surgery is worth the risk of the node growing during the pre-surgical window.

L.P., 67, who spent thirty-one years sorting mail on foot and treated a slow-growing sole lesion as a stubborn callus for over a year. The disagreement is whether her specific melanoma subtype actually shares in evidence drawn almost entirely from a different one.

W.B., 74, a retired furniture maker whose steady hands and long standing hours have grown harder to manage, responding well to a drug whose side effects have become genuinely unlivable. The disagreement is whether a switch counts as intolerance under the real letter of the label.

H.N., 68, his wife's primary caregiver through her progressing dementia, carrying a kidney transplant of many years alongside an advancing skin cancer. The disagreement is whether protecting the graft first can be reconciled with a cancer that isn't waiting.

V.A., 79, whose forty-year vegetable garden finally went unweeded when a fast-growing scalp nodule alarmed her daughter. The disagreement is whether a rising bilirubin justifies a chemotherapy bridge before immunotherapy, or whether that instinct trades away the better long-term option for an unproven short-term one.

F.J., 71, who still climbs a stepladder for his own apple orchard despite family objections, his rheumatoid arthritis well controlled on methotrexate. The disagreement is whether a local, injectable therapy is the safer path around a systemic checkpoint inhibitor that could flare his joints.

P.S., 68, four years into a metastatic GIST diagnosis that has barely interrupted his morning river routine, now progressing on imatinib. The disagreement is whether his tumor's specific secondary mutation site should override the standard next-line sequence entirely.

C.W., 57, running his family's 400-acre grain farm through hands swollen most mornings from the very drug meant to protect him. The disagreement is whether his unusually high individual recurrence risk justifies extending adjuvant therapy past the standard three years.

Renata S., 34, a fourth-grade teacher who chalked up a deep thigh ache to an old soccer injury until it grew too large to ignore. The disagreement is whether a trial's average result across many sarcoma types undersells what her specific histology's own known sensitivity actually predicts.

R.T., 71, a retired accountant who says his whole career trained him to want a clear number before deciding anything. The disagreement is whether a HER2 signal on broad genomic profiling is trustworthy enough to act on when no trial has ever tested it in a cancer with no known primary.